Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions
Steroid-Sensitive Nephrotic Syndrome
Interventions
DRUG

Rituximab

Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission

Trial Locations (8)

201102

Children's Hospital of Fudan University, Shanghai

Unknown

Anhui Provincial Children's Hospital, Hefei

Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital, Zhengzhou

Wuhan Children's Hospital,Tongji Medical College, Huazhong University of Science and Technology., Wuhan

Children's Hospital of Nanjing Medical University, Nanjing

The First Affiliated Hospital of Zhongshan University, Guanzhou

Shandong Provincial Hospital Affiliated to Shandong University, Shandong

Xuzhou Children's Hospital, Xuzhou

All Listed Sponsors
collaborator

Children's Hospital of Nanjing Medical University

OTHER

collaborator

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

collaborator

Anhui Provincial Children's Hospital

OTHER

collaborator

Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital

UNKNOWN

collaborator

The first affiliated hospital of Zhongshan university

UNKNOWN

collaborator

Shandong Provincial Hospital

OTHER_GOV

collaborator

Xuzhou Children Hospital

OTHER

lead

Children's Hospital of Fudan University

OTHER